JP2023512441A5 - - Google Patents
Info
- Publication number
- JP2023512441A5 JP2023512441A5 JP2022542475A JP2022542475A JP2023512441A5 JP 2023512441 A5 JP2023512441 A5 JP 2023512441A5 JP 2022542475 A JP2022542475 A JP 2022542475A JP 2022542475 A JP2022542475 A JP 2022542475A JP 2023512441 A5 JP2023512441 A5 JP 2023512441A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- seq
- optionally
- antisense strand
- nucleoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025207980A JP2026062645A (ja) | 2020-01-10 | 2025-11-28 | 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959398P | 2020-01-10 | 2020-01-10 | |
| US202062959590P | 2020-01-10 | 2020-01-10 | |
| US202062959469P | 2020-01-10 | 2020-01-10 | |
| US62/959,398 | 2020-01-10 | ||
| US62/959,469 | 2020-01-10 | ||
| US62/959,590 | 2020-01-10 | ||
| PCT/US2021/012650 WO2021142227A1 (en) | 2020-01-10 | 2021-01-08 | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025207980A Division JP2026062645A (ja) | 2020-01-10 | 2025-11-28 | 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023512441A JP2023512441A (ja) | 2023-03-27 |
| JP2023512441A5 true JP2023512441A5 (OSRAM) | 2024-01-17 |
| JP7858532B2 JP7858532B2 (ja) | 2026-05-14 |
Family
ID=76788282
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542475A Active JP7858532B2 (ja) | 2020-01-10 | 2021-01-08 | 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用 |
| JP2025207980A Pending JP2026062645A (ja) | 2020-01-10 | 2025-11-28 | 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025207980A Pending JP2026062645A (ja) | 2020-01-10 | 2025-11-28 | 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230111147A1 (OSRAM) |
| EP (1) | EP4087586A4 (OSRAM) |
| JP (2) | JP7858532B2 (OSRAM) |
| CN (1) | CN115335062A (OSRAM) |
| CA (1) | CA3163283A1 (OSRAM) |
| WO (1) | WO2021142227A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3768386A4 (en) | 2018-03-23 | 2022-04-13 | University of Massachusetts | GENE THERAPY FOR THE TREATMENT OF BONE DISORDERS |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP7611825B2 (ja) | 2018-08-02 | 2025-01-10 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| KR20220125802A (ko) * | 2020-01-10 | 2022-09-14 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도 |
| IL294479A (en) * | 2020-01-10 | 2022-09-01 | Dyne Therapeutics Inc | Muscle targeting complexes and their uses for the treatment of myotonic dystrophy |
| US12624120B2 (en) | 2020-01-31 | 2026-05-12 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TfR) antibody and uses thereof |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| CN117980006A (zh) | 2021-07-09 | 2024-05-03 | 达因疗法公司 | 用于治疗肌养蛋白病的肌肉靶向复合物和制剂 |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US20250250564A2 (en) | 2021-12-22 | 2025-08-07 | Sapreme Technologies B.V. | Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders |
| KR20240121778A (ko) | 2021-12-22 | 2024-08-09 | 사프렘 테크놀로지스 비.브이. | 근육 소모 장애의 치료를 위한 표적화된 사포닌-핵산 접합체 |
| IL313731A (en) | 2021-12-22 | 2024-08-01 | Sapreme Tech Bv | Preparations containing nucleic acids and sponges aimed at treating muscle wasting diseases |
| WO2023201318A1 (en) * | 2022-04-15 | 2023-10-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| KR20250004770A (ko) * | 2022-04-15 | 2025-01-08 | 다인 세라퓨틱스, 인크. | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제 |
| US20250283078A1 (en) * | 2022-05-26 | 2025-09-11 | Board Of Regents Of The University Of Nebraska | Rna compositions and therapeutic methods thereof |
| EP4698656A1 (en) * | 2023-04-20 | 2026-02-25 | University of Massachusetts | Rna therapeutics for fibrodysplasia ossificans progressiva and uses thereof |
| WO2024220758A1 (en) * | 2023-04-20 | 2024-10-24 | University Of Massachusetts | Rnas targeting activin a subunits |
| WO2025160275A1 (en) | 2024-01-24 | 2025-07-31 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007104971A (ja) * | 2005-10-14 | 2007-04-26 | New Industry Research Organization | ミオスタチンのスプライシング制御アンチセンスオリゴヌクレオチド |
| US8309614B2 (en) * | 2008-04-11 | 2012-11-13 | Cedars-Sinai Medical Center | Poly(beta malic acid) with pendant leu-leu-leu tripeptide for effective cytoplasmic drug delivery |
| GB0904214D0 (en) * | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| WO2012075037A1 (en) * | 2010-11-30 | 2012-06-07 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses therefor |
| CA2929574A1 (en) * | 2013-11-11 | 2015-05-14 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety |
| CN103882024A (zh) * | 2014-04-21 | 2014-06-25 | 石河子大学 | 一种RNAi干扰片段、RNAi干扰载体及其应用 |
| JP6779876B2 (ja) * | 2014-11-19 | 2020-11-04 | ジェネンテック， インコーポレイテッド | 抗トランスフェリン受容体抗体及びその使用方法 |
| US20190240346A1 (en) * | 2016-06-20 | 2019-08-08 | Genahead Bio, Inc. | Antibody-drug conjugate |
| EP3516062A1 (en) * | 2016-09-21 | 2019-07-31 | Alnylam Pharmaceuticals, Inc. | Myostatin irna compositions and methods of use thereof |
| NZ752703A (en) * | 2016-12-26 | 2022-09-30 | Japan Chem Res | Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier |
| CN118638788A (zh) | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| SG11202006433PA (en) * | 2018-02-05 | 2020-08-28 | Jcr Pharmaceuticals Co Ltd | Method for delivering drug to muscle |
| US20220378934A1 (en) * | 2018-08-02 | 2022-12-01 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof in treating muscle atrophy |
-
2021
- 2021-01-08 CN CN202180018131.0A patent/CN115335062A/zh active Pending
- 2021-01-08 EP EP21738475.9A patent/EP4087586A4/en active Pending
- 2021-01-08 WO PCT/US2021/012650 patent/WO2021142227A1/en not_active Ceased
- 2021-01-08 CA CA3163283A patent/CA3163283A1/en active Pending
- 2021-01-08 US US17/791,670 patent/US20230111147A1/en active Pending
- 2021-01-08 JP JP2022542475A patent/JP7858532B2/ja active Active
-
2025
- 2025-11-28 JP JP2025207980A patent/JP2026062645A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023510351A5 (OSRAM) | ||
| JP2023512442A5 (OSRAM) | ||
| JP2023509793A5 (OSRAM) | ||
| JP2021533199A5 (OSRAM) | ||
| JP2024525614A5 (OSRAM) | ||
| JP2022513482A5 (OSRAM) | ||
| JP2023510350A5 (OSRAM) | ||
| JP2023535078A5 (OSRAM) | ||
| JP2023535073A5 (OSRAM) | ||
| JP2021533200A5 (OSRAM) | ||
| JP2021532832A5 (OSRAM) | ||
| JP7803926B2 (ja) | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 | |
| JP2024524222A5 (OSRAM) | ||
| JP2021533197A5 (OSRAM) | ||
| JP2022122928A5 (OSRAM) | ||
| IL274906B2 (en) | Compositions and methods for treating muscular dystrophy and myotonic dystrophy | |
| JP2023535444A5 (OSRAM) | ||
| JP2025067909A5 (OSRAM) | ||
| IL317871A (en) | Muscle targeting complexes and their uses for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy | |
| JP2020505330A5 (OSRAM) | ||
| JP2024527362A5 (OSRAM) | ||
| JP2024535797A5 (OSRAM) | ||
| JP2021533198A5 (OSRAM) | ||
| JP2024525612A5 (OSRAM) | ||
| JP2024503609A5 (OSRAM) |